Fresenius Kabi
Nov 08, 2016
Fresenius Kabi introduced Bivalirudin; Envigo Launches; Mylan’s MAA accepted; Pricing hit pharma
Fresenius Kabi introduced Bivalirudin for Injection Fresenius Kabi announced that it has introduced Bivalirudin for Injection in the United States, which is an anticoagulant, and a generic alternative to Angiomax. Fresenius Kabi’s Bivalirudin was approved by the U.S. Food and Drug Administration in October. The U.S....
Read More...
-Agonist.png "Toll-like Receptors Agonist")
